Ignite Creation Date:
2025-12-24 @ 2:02 PM
Ignite Modification Date:
2026-02-02 @ 9:05 AM
Study NCT ID:
NCT02962895
Status:
COMPLETED
Last Update Posted:
2025-01-07
First Post:
2016-11-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2022-08-10', 'type': 'ACTUAL'}}}}, 'interventionBrowseModule': {'meshes': [{'id': 'C000656267', 'term': 'ianalumab'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'novartis.email@novartis.com', 'phone': '+1 (862) 778-8300', 'title': 'Study Director', 'organization': 'Novartis Pharmaceuticals'}, 'certainAgreement': {'otherDetails': "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From first dose of study drug until end of follow-up period, up to approximately 3 years (max duration of follow-up was 2 years).', 'description': 'An adverse event is any sign or symptom that occurs during the conduct of the trial and safety follow-up.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)', 'otherNumAtRisk': 49, 'deathsNumAtRisk': 49, 'otherNumAffected': 33, 'seriousNumAtRisk': 49, 'deathsNumAffected': 0, 'seriousNumAffected': 3}, {'id': 'EG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)', 'otherNumAtRisk': 47, 'deathsNumAtRisk': 47, 'otherNumAffected': 40, 'seriousNumAtRisk': 47, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)', 'otherNumAtRisk': 47, 'deathsNumAtRisk': 47, 'otherNumAffected': 34, 'seriousNumAtRisk': 47, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)', 'otherNumAtRisk': 47, 'deathsNumAtRisk': 47, 'otherNumAffected': 41, 'seriousNumAtRisk': 47, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG004', 'title': 'Any VAY736 (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)', 'otherNumAtRisk': 141, 'deathsNumAtRisk': 141, 'otherNumAffected': 115, 'seriousNumAtRisk': 141, 'deathsNumAffected': 0, 'seriousNumAffected': 3}, {'id': 'EG005', 'title': 'ALL (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)', 'otherNumAtRisk': 190, 'deathsNumAtRisk': 190, 'otherNumAffected': 148, 'seriousNumAtRisk': 190, 'deathsNumAffected': 0, 'seriousNumAffected': 6}, {'id': 'EG006', 'title': 'VAY736 - 5 mg 24 Weeks (Periods 2 and 4)', 'description': 'All events reported from start of VAY736 - 5 mg dose in Period 2 (blinded treatment period of 24 weeks) and in the post treatment safety follow-up (Period 4)', 'otherNumAtRisk': 47, 'deathsNumAtRisk': 47, 'otherNumAffected': 41, 'seriousNumAtRisk': 47, 'deathsNumAffected': 0, 'seriousNumAffected': 3}, {'id': 'EG007', 'title': 'VAY736 - 50 mg 24 Weeks (Periods 2 and 4)', 'description': 'All events reported from start of VAY736 - 50 mg dose in Period 2 (blinded treatment period of 24 weeks) and in the post treatment safety follow-up (Period 4)', 'otherNumAtRisk': 47, 'deathsNumAtRisk': 47, 'otherNumAffected': 37, 'seriousNumAtRisk': 47, 'deathsNumAffected': 0, 'seriousNumAffected': 7}, {'id': 'EG008', 'title': 'VAY736 - 150 mg 28 Weeks (Periods 3 and 4)', 'description': 'All events reported from start of VAY736 - 150 mg dose in Period 3 (extended blinded treatment period of 28 weeks) up to the end of post treatment safety follow-up (Period 4)', 'otherNumAtRisk': 47, 'deathsNumAtRisk': 47, 'otherNumAffected': 41, 'seriousNumAtRisk': 47, 'deathsNumAffected': 0, 'seriousNumAffected': 9}, {'id': 'EG009', 'title': 'VAY736 - 300 mg 24 Weeks (Entire Study)', 'description': 'All events reported from the beginning of the study up until the end of post treatment safety follow-up (Period 4)', 'otherNumAtRisk': 26, 'deathsNumAtRisk': 26, 'otherNumAffected': 24, 'seriousNumAtRisk': 26, 'deathsNumAffected': 0, 'seriousNumAffected': 5}, {'id': 'EG010', 'title': 'VAY736 - 300 mg 52 Weeks (Entire Study)', 'description': 'All events reported from the beginning of the study up until the end of post treatment safety follow-up (Period 4)', 'otherNumAtRisk': 21, 'deathsNumAtRisk': 21, 'otherNumAffected': 20, 'seriousNumAtRisk': 21, 'deathsNumAffected': 0, 'seriousNumAffected': 5}, {'id': 'EG011', 'title': 'Any VAY736 - 300 mg (Periods 2, 3 and 4)', 'description': 'All events reported from the beginning of the study up until the end of post treatment safety follow-up (Period 4)', 'otherNumAtRisk': 47, 'deathsNumAtRisk': 47, 'otherNumAffected': 44, 'seriousNumAtRisk': 47, 'deathsNumAffected': 0, 'seriousNumAffected': 10}, {'id': 'EG012', 'title': 'Any VAY736 (Periods 2, 3 and 4)', 'description': 'All events reported from the beginning of the study up until the end of post treatment safety follow-up (Period 4)', 'otherNumAtRisk': 188, 'deathsNumAtRisk': 188, 'otherNumAffected': 163, 'seriousNumAtRisk': 188, 'deathsNumAffected': 0, 'seriousNumAffected': 29}], 'otherEvents': [{'term': 'Iron deficiency anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 4}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 6}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 11}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 13}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 4}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 6}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 15}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Lymphopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 11}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 13}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 9}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 12}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 5}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 12}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 3}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 4}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 7}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 15}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Gastrooesophageal reflux disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 6}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 6}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Mouth ulceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 5}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Influenza like illness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 9}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Injection site reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 9}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 26}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 39}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 41}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 9}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 17}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 13}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 14}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 27}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 57}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 6}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 5}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 3}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 7}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Acute sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 9}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 14}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Conjunctivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 10}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 5}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 12}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 7}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 3}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 5}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 13}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 18}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 7}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 11}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 5}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 4}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 9}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 31}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Oral candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Oral herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 3}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 12}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Parotitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 10}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 7}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 18}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Tracheobronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 11}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 15}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 7}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 9}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 7}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 8}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 10}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 33}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 12}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 9}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 5}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 7}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 3}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 5}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 26}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Viral upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Animal bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 3}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Arthropod bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 5}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 5}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Injection related reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 15}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 17}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 6}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 5}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 7}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 22}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Wound', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 3}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 6}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Lymphocyte count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 7}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Neutrophil count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 6}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'White blood cell count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 6}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 6}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 5}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 10}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 6}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 3}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 5}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 15}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 10}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 6}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 4}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 6}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 19}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Joint swelling', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 5}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Muscle spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 4}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Myalgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 9}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 11}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': "Sjogren's syndrome", 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 7}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 7}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 12}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 19}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 5}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 5}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 4}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 6}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 20}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Polyneuropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 2}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 3}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 6}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Dysuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 3}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 7}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Nasal congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 3}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Productive cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 3}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 4}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 5}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 8}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 10}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 6}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 3}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 15}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 4}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 8}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}], 'seriousEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Deafness neurosensory', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pancreatic disorder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cholelithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 2}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 2}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 2}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Cell-mediated immune deficiency', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Immune system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Appendicitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'COVID-19', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'COVID-19 pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Candida infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Gastroenteritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Respiratory syncytial virus bronchiolitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Tubo-ovarian abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Wound infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Femoral neck fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Forearm fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Injection related reaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Thoracic vertebral fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Traumatic fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Weight decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': "Sjogren's syndrome", 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Breast cancer metastatic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Extranodal marginal zone B-cell lymphoma (MALT type)', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Migraine', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Syncope', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Device breakage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Product Issues', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Renal colic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Rash', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}, {'term': 'Vasculitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 49, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 141, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 190, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 47, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 26, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 21, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 47, 'numAffected': 0}, {'groupId': 'EG012', 'numAtRisk': 188, 'numAffected': 1}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (24.0)'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Least Squares Mean Change From Baseline in ESSDAI Score at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'categories': [{'measurements': [{'value': '-6.39', 'spread': '0.808', 'groupId': 'OG000'}, {'value': '-5.64', 'spread': '0.850', 'groupId': 'OG001'}, {'value': '-6.93', 'spread': '0.836', 'groupId': 'OG002'}, {'value': '-8.30', 'spread': '0.828', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.5161', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.75', 'ciLowerLimit': '-1.52', 'ciUpperLimit': '3.02', 'groupDescription': 'Week 24: VAY736 5 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.6332', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.55', 'ciLowerLimit': '-2.80', 'ciUpperLimit': '1.71', 'groupDescription': 'Week 24: VAY736 50 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.0921', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.92', 'ciLowerLimit': '-4.15', 'ciUpperLimit': '0.32', 'groupDescription': 'Week 24: VAY736 300 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'description': "The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status.", 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS)'}, {'type': 'SECONDARY', 'title': 'Least Squares Mean Change From Baseline in ESSDAI Score at Weeks 4, 8, 12, and 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '46', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-3.73', 'spread': '0.626', 'groupId': 'OG000'}, {'value': '-2.28', 'spread': '0.661', 'groupId': 'OG001'}, {'value': '-3.37', 'spread': '0.638', 'groupId': 'OG002'}, {'value': '-4.53', 'spread': '0.651', 'groupId': 'OG003'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '44', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-4.13', 'spread': '0.704', 'groupId': 'OG000'}, {'value': '-4.65', 'spread': '0.733', 'groupId': 'OG001'}, {'value': '-4.73', 'spread': '0.720', 'groupId': 'OG002'}, {'value': '-6.38', 'spread': '0.717', 'groupId': 'OG003'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '44', 'groupId': 'OG001'}, {'value': '45', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-5.45', 'spread': '0.721', 'groupId': 'OG000'}, {'value': '-4.89', 'spread': '0.762', 'groupId': 'OG001'}, {'value': '-5.69', 'spread': '0.739', 'groupId': 'OG002'}, {'value': '-6.64', 'spread': '0.739', 'groupId': 'OG003'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '46', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-6.08', 'spread': '0.818', 'groupId': 'OG000'}, {'value': '-5.67', 'spread': '0.852', 'groupId': 'OG001'}, {'value': '-6.17', 'spread': '0.835', 'groupId': 'OG002'}, {'value': '-6.99', 'spread': '0.836', 'groupId': 'OG003'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 4, Week 8, Week 12, Week 16', 'description': "The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status.", 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS). Only participants with a value at both Baseline and post-baseline visit included.'}, {'type': 'SECONDARY', 'title': 'Least Squares Mean Change From Baseline in ESSPRI Score at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'categories': [{'measurements': [{'value': '-1.71', 'spread': '0.288', 'groupId': 'OG000'}, {'value': '-1.39', 'spread': '0.304', 'groupId': 'OG001'}, {'value': '-1.70', 'spread': '0.301', 'groupId': 'OG002'}, {'value': '-1.77', 'spread': '0.295', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.4457', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.32', 'ciLowerLimit': '-0.50', 'ciUpperLimit': '1.13', 'groupDescription': 'Week 24: VAY736 5 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.301', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least Square Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.01', 'ciLowerLimit': '-0.79', 'ciUpperLimit': '0.82', 'groupDescription': 'Week 24: VAY736 50 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.8858', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least Square Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.06', 'ciLowerLimit': '-0.86', 'ciUpperLimit': '0.74', 'groupDescription': 'Week 24: VAY736 300 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'description': "The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome.", 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS)'}, {'type': 'SECONDARY', 'title': 'Least Squares Mean Change From Baseline in ESSPRI Score at Weeks 4, 8, 12 and 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '46', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-0.54', 'spread': '0.236', 'groupId': 'OG000'}, {'value': '-0.67', 'spread': '0.247', 'groupId': 'OG001'}, {'value': '-0.80', 'spread': '0.241', 'groupId': 'OG002'}, {'value': '-0.88', 'spread': '0.242', 'groupId': 'OG003'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-0.94', 'spread': '0.242', 'groupId': 'OG000'}, {'value': '-0.84', 'spread': '0.255', 'groupId': 'OG001'}, {'value': '-1.06', 'spread': '0.251', 'groupId': 'OG002'}, {'value': '-1.8', 'spread': '0.248', 'groupId': 'OG003'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '44', 'groupId': 'OG001'}, {'value': '45', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-1.42', 'spread': '0.265', 'groupId': 'OG000'}, {'value': '-1.36', 'spread': '0.279', 'groupId': 'OG001'}, {'value': '-1.44', 'spread': '0.273', 'groupId': 'OG002'}, {'value': '-1.23', 'spread': '0.270', 'groupId': 'OG003'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '46', 'groupId': 'OG001'}, {'value': '45', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-1.77', 'spread': '0.263', 'groupId': 'OG000'}, {'value': '-1.27', 'spread': '0.275', 'groupId': 'OG001'}, {'value': '-1.55', 'spread': '0.271', 'groupId': 'OG002'}, {'value': '-1.55', 'spread': '0.270', 'groupId': 'OG003'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 4, Week 8, Week 12, Week 16', 'description': "The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome.", 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS). Only participants with a value at both Baseline and post-baseline visit included.'}, {'type': 'SECONDARY', 'title': 'Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score Over 24 Weeks', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'categories': [{'measurements': [{'value': '9.05', 'spread': '1.404', 'groupId': 'OG000'}, {'value': '7.12', 'spread': '1.502', 'groupId': 'OG001'}, {'value': '6.48', 'spread': '1.518', 'groupId': 'OG002'}, {'value': '9.36', 'spread': '1.436', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.3424', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.93', 'ciLowerLimit': '-5.93', 'ciUpperLimit': '2.07', 'groupDescription': 'Week 24: VAY736 5 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values are derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.2092', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.56', 'ciLowerLimit': '-6.58', 'ciUpperLimit': '1.45', 'groupDescription': 'Week 24: VAY736 50 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values are derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.8740', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.31', 'ciLowerLimit': '-3.58', 'ciUpperLimit': '4.20', 'groupDescription': 'Week 24: VAY736 300 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values are derived from a mixed model for repeated measures (MMRM)'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'description': "The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue.", 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS)'}, {'type': 'SECONDARY', 'title': 'Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score at Weeks 4, 8, 12 and 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '42', 'groupId': 'OG001'}, {'value': '39', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'title': 'Week 4', 'categories': [{'measurements': [{'value': '3.78', 'spread': '1.175', 'groupId': 'OG000'}, {'value': '6.32', 'spread': '1.239', 'groupId': 'OG001'}, {'value': '3.12', 'spread': '1.229', 'groupId': 'OG002'}, {'value': '3.39', 'spread': '1.203', 'groupId': 'OG003'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'value': '5.49', 'spread': '1.222', 'groupId': 'OG000'}, {'value': '6.36', 'spread': '1.297', 'groupId': 'OG001'}, {'value': '3.93', 'spread': '1.303', 'groupId': 'OG002'}, {'value': '5.98', 'spread': '1.250', 'groupId': 'OG003'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'value': '6.25', 'spread': '1.349', 'groupId': 'OG000'}, {'value': '8.17', 'spread': '1.429', 'groupId': 'OG001'}, {'value': '5.73', 'spread': '1.427', 'groupId': 'OG002'}, {'value': '6.05', 'spread': '1.374', 'groupId': 'OG003'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'value': '8.56', 'spread': '1.284', 'groupId': 'OG000'}, {'value': '7.09', 'spread': '1.357', 'groupId': 'OG001'}, {'value': '6.86', 'spread': '1.359', 'groupId': 'OG002'}, {'value': '8.30', 'spread': '1.318', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Weeks 4, 8, 12 and 16', 'description': "The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue.", 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS). Only participants with a value at both Baseline and post-baseline visit included.'}, {'type': 'SECONDARY', 'title': 'Least Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) Over 24 Weeks', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'title': 'Mental Component Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '42', 'groupId': 'OG001'}, {'value': '39', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '4.63', 'spread': '1.259', 'groupId': 'OG000'}, {'value': '3.61', 'spread': '1.350', 'groupId': 'OG001'}, {'value': '5.31', 'spread': '1.367', 'groupId': 'OG002'}, {'value': '5.63', 'spread': '1.286', 'groupId': 'OG003'}]}]}, {'title': 'Physical Component Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '42', 'groupId': 'OG001'}, {'value': '39', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3.66', 'spread': '0.952', 'groupId': 'OG000'}, {'value': '4.79', 'spread': '1.019', 'groupId': 'OG001'}, {'value': '2.66', 'spread': '1.026', 'groupId': 'OG002'}, {'value': '5.50', 'spread': '0.972', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.5768', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.02', 'ciLowerLimit': '-4.61', 'ciUpperLimit': '2.57', 'groupDescription': 'Week 24: VAY736 5 mg vs. Placebo / Mental Component Score', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.7113', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.68', 'ciLowerLimit': '-2.93', 'ciUpperLimit': '4.28', 'groupDescription': 'Week 24: VAY736 50 mg vs. Placebo / Mental Component Score', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.5722', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.00', 'ciLowerLimit': '-2.49', 'ciUpperLimit': '4.48', 'groupDescription': 'Week 24: VAY736 300 mg vs. Placebo / Mental Component Score', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.4138', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.84', 'ciLowerLimit': '-1.59', 'ciUpperLimit': '3.83', 'groupDescription': 'Week 24: VAY736 5 mg vs. Placebo / Physical Component Score', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.4663', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-1.00', 'ciLowerLimit': '-3.72', 'ciUpperLimit': '1.71', 'groupDescription': 'Week 24: VAY736 50 mg vs. Placebo / Physical Component Score', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.1694', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.84', 'ciLowerLimit': '-0.79', 'ciUpperLimit': '4.47', 'groupDescription': 'Week 24: VAY736 300 mg vs. Placebo / Physical Component Score', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24', 'description': 'The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS)'}, {'type': 'SECONDARY', 'title': 'Least Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) at Weeks 4, 8, 12 and 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'title': 'Week 4 - Mental Component Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '44', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.49', 'spread': '1.091', 'groupId': 'OG000'}, {'value': '1.89', 'spread': '1.151', 'groupId': 'OG001'}, {'value': '2.46', 'spread': '1.149', 'groupId': 'OG002'}, {'value': '2.18', 'spread': '1.116', 'groupId': 'OG003'}]}]}, {'title': 'Week 8 - Mental Component Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '44', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '2.65', 'spread': '2.267', 'groupId': 'OG000'}, {'value': '3.80', 'spread': '1.341', 'groupId': 'OG001'}, {'value': '4.65', 'spread': '1.363', 'groupId': 'OG002'}, {'value': '3.35', 'spread': '1.294', 'groupId': 'OG003'}]}]}, {'title': 'Week 12 - Mental Component Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '44', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '2.89', 'spread': '1.188', 'groupId': 'OG000'}, {'value': '5.42', 'spread': '1.264', 'groupId': 'OG001'}, {'value': '3.94', 'spread': '1.265', 'groupId': 'OG002'}, {'value': '4.59', 'spread': '1.207', 'groupId': 'OG003'}]}]}, {'title': 'Week 16 - Mental Component Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '4.60', 'spread': '1.214', 'groupId': 'OG000'}, {'value': '3.00', 'spread': '1.281', 'groupId': 'OG001'}, {'value': '5.57', 'spread': '1.291', 'groupId': 'OG002'}, {'value': '5.46', 'spread': '1.247', 'groupId': 'OG003'}]}]}, {'title': 'Week 4 - Physical Component Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '44', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3.35', 'spread': '0.844', 'groupId': 'OG000'}, {'value': '3.94', 'spread': '0.889', 'groupId': 'OG001'}, {'value': '1.14', 'spread': '0.878', 'groupId': 'OG002'}, {'value': '1.98', 'spread': '0.863', 'groupId': 'OG003'}]}]}, {'title': 'Week 8 - Physical Component Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '44', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3.83', 'spread': '0.894', 'groupId': 'OG000'}, {'value': '4.56', 'spread': '0.949', 'groupId': 'OG001'}, {'value': '3.48', 'spread': '0.941', 'groupId': 'OG002'}, {'value': '3.47', 'spread': '0.909', 'groupId': 'OG003'}]}]}, {'title': 'Week 12 - Physical Component Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '44', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '3.83', 'spread': '0.894', 'groupId': 'OG000'}, {'value': '4.56', 'spread': '0.949', 'groupId': 'OG001'}, {'value': '3.48', 'spread': '0.941', 'groupId': 'OG002'}, {'value': '3.47', 'spread': '0.909', 'groupId': 'OG003'}]}]}, {'title': 'Week 16 - Physical Component Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '4.72', 'spread': '0.968', 'groupId': 'OG000'}, {'value': '4.67', 'spread': '1.020', 'groupId': 'OG001'}, {'value': '3.32', 'spread': '1.021', 'groupId': 'OG002'}, {'value': '4.57', 'spread': '0.993', 'groupId': 'OG003'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Weeks 4, 8, 12 and 16', 'description': 'The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS): Only participants with a value at both Baseline and post-baseline visit included.'}, {'type': 'SECONDARY', 'title': "Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) Over 24 Weeks", 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'categories': [{'measurements': [{'value': '-23.64', 'spread': '2.601', 'groupId': 'OG000'}, {'value': '-27.81', 'spread': '2.751', 'groupId': 'OG001'}, {'value': '-28.13', 'spread': '2.700', 'groupId': 'OG002'}, {'value': '-31.99', 'spread': '2.630', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.2671', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.17', 'ciLowerLimit': '-11.56', 'ciUpperLimit': '3.22', 'groupDescription': 'Week 24: VAY736 5 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.2248', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.49', 'ciLowerLimit': '-11.78', 'ciUpperLimit': '2.79', 'groupDescription': 'Week 24: VAY736 50 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.0224', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-8.36', 'ciLowerLimit': '-15.51', 'ciUpperLimit': '-1.20', 'groupDescription': 'Week 24: VAY736 300 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, 24 weeks', 'description': 'Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS)'}, {'type': 'SECONDARY', 'title': "Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) at Weeks 4, 8, 12 and 16", 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '43', 'groupId': 'OG001'}, {'value': '45', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-12.49', 'spread': '2.327', 'groupId': 'OG000'}, {'value': '-10.50', 'spread': '2.445', 'groupId': 'OG001'}, {'value': '-12.38', 'spread': '2.361', 'groupId': 'OG002'}, {'value': '-18.67', 'spread': '2.367', 'groupId': 'OG003'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-18.54', 'spread': '2.239', 'groupId': 'OG000'}, {'value': '-16.53', 'spread': '2.338', 'groupId': 'OG001'}, {'value': '-22.12', 'spread': '2.374', 'groupId': 'OG002'}, {'value': '-24.85', 'spread': '2.289', 'groupId': 'OG003'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-21.01', 'spread': '2.299', 'groupId': 'OG000'}, {'value': '-20.72', 'spread': '2.413', 'groupId': 'OG001'}, {'value': '-25.35', 'spread': '2.341', 'groupId': 'OG002'}, {'value': '-27.25', 'spread': '2.305', 'groupId': 'OG003'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-19.44', 'spread': '2.572', 'groupId': 'OG000'}, {'value': '-24.49', 'spread': '2.687', 'groupId': 'OG001'}, {'value': '-24.77', 'spread': '2.676', 'groupId': 'OG002'}, {'value': '-25.77', 'spread': '2.633', 'groupId': 'OG003'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Weeks 4, 8, 12 and 16', 'description': 'Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS). Only participants with a value at both Baseline and post-baseline visit included.'}, {'type': 'SECONDARY', 'title': "Patient's Global Assessment (PaGA) Score at Weeks 4, 8, 12, 16 and 24", 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '45', 'groupId': 'OG001'}, {'value': '44', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-9.42', 'spread': '2.850', 'groupId': 'OG000'}, {'value': '-10.02', 'spread': '2.992', 'groupId': 'OG001'}, {'value': '-5.96', 'spread': '2.969', 'groupId': 'OG002'}, {'value': '-8.96', 'spread': '2.906', 'groupId': 'OG003'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '44', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-9.74', 'spread': '3.035', 'groupId': 'OG000'}, {'value': '-11.48', 'spread': '3.214', 'groupId': 'OG001'}, {'value': '-8.70', 'spread': '3.271', 'groupId': 'OG002'}, {'value': '-15.27', 'spread': '3.091', 'groupId': 'OG003'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '48', 'groupId': 'OG000'}, {'value': '44', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-11.45', 'spread': '3.064', 'groupId': 'OG000'}, {'value': '-17.51', 'spread': '3.244', 'groupId': 'OG001'}, {'value': '-11.73', 'spread': '3.234', 'groupId': 'OG002'}, {'value': '-13.57', 'spread': '3.105', 'groupId': 'OG003'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-16.26', 'spread': '3.194', 'groupId': 'OG000'}, {'value': '-17.56', 'spread': '3.361', 'groupId': 'OG001'}, {'value': '-14.86', 'spread': '3.375', 'groupId': 'OG002'}, {'value': '-15.78', 'spread': '3.271', 'groupId': 'OG003'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-15.11', 'spread': '3.405', 'groupId': 'OG000'}, {'value': '-12.83', 'spread': '3.648', 'groupId': 'OG001'}, {'value': '-11.85', 'spread': '3.704', 'groupId': 'OG002'}, {'value': '-19.87', 'spread': '3.470', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.6457', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '2.27', 'ciLowerLimit': '-7.46', 'ciUpperLimit': '12.00', 'groupDescription': 'Week 24: VAY736 5 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.5132', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '3.26', 'ciLowerLimit': '-6.55', 'ciUpperLimit': '13.06', 'groupDescription': 'Week 24: VAY736 50 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '95', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-4.77', 'ciLowerLimit': '-14.21', 'ciUpperLimit': '4.68', 'groupDescription': 'Week 24: VAY736 300 mg vs. Placebo', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Weeks 4, 8, 12, 16 and 24', 'description': 'The PaGA of disease activity was performed using a 100 mm Visual Analog Scale (VAS) ranging from 0 (no disease activity) to 100 (maximal disease activity), in response to the question "Considering all the ways Sjögren\'s syndrome affects you, please draw a line on the scale to indicate how well you are doing today". A negative change from baseline is a favourable outcome.', 'unitOfMeasure': 'Scores on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full Analysis Set (FAS). Only participants with a value at both Baseline and post-baseline visit included.'}, {'type': 'SECONDARY', 'title': 'Least Squares Mean Change From Baseline in Salivary Flow Rate at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '47', 'groupId': 'OG002'}, {'value': '47', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}], 'classes': [{'title': 'Stimulated', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '40', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.067', 'groupId': 'OG000'}, {'value': '0.16', 'spread': '0.074', 'groupId': 'OG001'}, {'value': '0.18', 'spread': '0.071', 'groupId': 'OG002'}, {'value': '0.25', 'spread': '0.98', 'groupId': 'OG003'}]}]}, {'title': 'Unstimulated', 'denoms': [{'units': 'Participants', 'counts': [{'value': '46', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.030', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.034', 'groupId': 'OG001'}, {'value': '-0.00', 'spread': '0.032', 'groupId': 'OG002'}, {'value': '-0.01', 'spread': '0.031', 'groupId': 'OG003'}]}]}], 'analyses': [{'pValue': '0.2710', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.11', 'ciLowerLimit': '-0.08', 'ciUpperLimit': '0.30', 'groupDescription': 'Week 24: VAY736 5 mg vs. Placebo (Stimulated salivary flow rate)', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.1618', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.13', 'ciLowerLimit': '-0.05', 'ciUpperLimit': '0.32', 'groupDescription': 'Week 24: VAY736 50 mg vs. Placebo (Stimulated salivary flow rate)', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.0374', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.20', 'ciLowerLimit': '0.01', 'ciUpperLimit': '0.38', 'groupDescription': 'Week 24: VAY736 300 mg vs. Placebo (Stimulated salivary flow rate)', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.9559', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.00', 'ciLowerLimit': '-0.09', 'ciUpperLimit': '0.09', 'groupDescription': 'Week 24: VAY736 5 mg vs. Placebo (Unstimulated salivary flow rate)', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.9290', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.00', 'ciLowerLimit': '-0.09', 'ciUpperLimit': '0.08', 'groupDescription': 'Week 24: VAY736 50 mg vs. Placebo (Unstimulated salivary flow rate)', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}, {'pValue': '0.7276', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Least Squares Mean Difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-0.01', 'ciLowerLimit': '-0.10', 'ciUpperLimit': '0.07', 'groupDescription': 'Week 24: VAY736 300 mg vs. Placebo (Unstimulated salivary flow rate)', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals and p-values derived from a mixed model for repeated measures (MMRM)'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, 24 weeks', 'description': 'Change from baseline in salivary flow rate (unstimulated and stimulated) at 24 weeks as compared to placebo.\n\nUnstimulated saliva is a mix of serous and mucous secretions coming primarily from the submandibular and minor salivary glands. The parotid gland produces the largest volume of stimulated saliva. Stimulated saliva accounts for 80-90% of daily salivary production.', 'unitOfMeasure': 'mL/min', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): The overall number of participants analyzed represents the FAS. The number analyzed per row represents participants with data available at each assessment.'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in Whole Blood CD19+ B-cell Counts.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '49', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '21', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'Placebo - VAY150 mg', 'description': 'Placebo control at 24 weeks VAY150g at 28 weeks'}, {'id': 'OG003', 'title': 'VAY736 300 mg - Placebo', 'description': 'VAY736 300 mg patients in Period 2 re-randomized to Placebo every 4 weeks in Period 3 (Period 3 = 28 weeks)'}, {'id': 'OG004', 'title': 'VAY736 300 mg - VAY736 300 mg', 'description': 'VAY736 300 mg patients in Period 2 re-randomized to VAY736 300 mg every 4 weeks in Period 3 (Period 3 = 28 weeks)'}], 'classes': [{'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'OG000'}, {'value': '34', 'groupId': 'OG001'}, {'value': '36', 'groupId': 'OG002'}, {'value': '17', 'groupId': 'OG003'}, {'value': '18', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-88.00', 'spread': '5.784', 'groupId': 'OG000'}, {'value': '-99.07', 'spread': '5.812', 'groupId': 'OG001'}, {'value': '3.29', 'spread': '5.674', 'groupId': 'OG002'}, {'value': '-103.0', 'spread': '8.198', 'groupId': 'OG003'}, {'value': '-94.20', 'spread': '8.098', 'groupId': 'OG004'}]}]}, {'title': 'Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '35', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}, {'value': '17', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '-97.06', 'spread': '5.732', 'groupId': 'OG002'}, {'value': '-105.3', 'spread': '9.145', 'groupId': 'OG003'}, {'value': '-91.80', 'spread': '8.272', 'groupId': 'OG004'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 24, Week 28', 'description': 'B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \\>= 50 cells/μL) were analyzed by descriptive statistics.\n\nBaseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.', 'unitOfMeasure': 'Percent change', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): patients were analyzed according to the first treatment received (at Period 2, 24 weeks). VAY736 300 mg - Placebo included patients who discontinued in Period 2 and entered Period 4 directly and patients who completed Period 2 and were re-randomized to placebo. Only patients with baseline measurement and at least one measurement post-baseline were included.'}, {'type': 'SECONDARY', 'title': 'Kaplan-Meier Analysis for Time to Recovery to Baseline Like Values for B-cell Counts', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '49', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '21', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'Placebo - VAY150 mg', 'description': 'Placebo control at week 24 VAY150 mg at week 28'}, {'id': 'OG003', 'title': 'VAY736 300 mg - Placebo', 'description': 'VAY736 300 mg patients in Period 2 re-randomized to Placebo every 4 weeks in Period 3 (Period 3 = 28 weeks)'}, {'id': 'OG004', 'title': 'VAY736 300 mg - VAY736 300 mg', 'description': 'VAY736 300 mg patients in Period 2 re-randomized to VAY736 300 mg every 4 weeks in Period 3 (Period 3 = 28 weeks)'}], 'classes': [{'categories': [{'measurements': [{'value': '3.8', 'groupId': 'OG000', 'lowerLimit': '2.7', 'upperLimit': '5.2'}, {'value': '4.8', 'groupId': 'OG001', 'lowerLimit': '4.7', 'upperLimit': '6.6'}, {'value': '6.8', 'groupId': 'OG002', 'lowerLimit': '5.0', 'upperLimit': '9.2'}, {'value': '8.4', 'groupId': 'OG003', 'lowerLimit': '6.8', 'upperLimit': '9.1'}, {'value': '6.5', 'groupId': 'OG004', 'lowerLimit': '4.9', 'upperLimit': '7.5'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Up to two years from last dose patient received.', 'description': 'B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \\>= 50 cells/μL) were analyzed by descriptive statistics.\n\nBaseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'Full analysis set (FAS): patients were analyzed according to the first treatment received (at Period 2, 24 weeks). VAY736 300 mg - Placebo included patients who discontinued in Period 2 and entered Period 4 directly and patients who completed Period 2 and were re-randomized to placebo. Only patients with baseline measurement and at least one measurement post-baseline were included.'}, {'type': 'SECONDARY', 'title': 'Peak Serum Concentration of VAY736', 'denoms': [{'units': 'Participants', 'counts': [{'value': '47', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '21', 'groupId': 'OG003'}, {'value': '22', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG001', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG002', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'OG003', 'title': 'VAY736 300 mg - Placebo', 'description': 'VAY736 300 mg patients in Period 2 re-randomized to Placebo every 4 weeks in Period 3 (Period 3 = 28 weeks)'}, {'id': 'OG004', 'title': 'VAY736 300 mg - VAY736 300 mg', 'description': 'VAY736 300 mg patients in Period 2 re-randomized to VAY736 300 mg every 4 weeks in Period 3 (Period 3 = 28 weeks)'}], 'classes': [{'categories': [{'measurements': [{'value': '0.0747', 'spread': '0.203', 'groupId': 'OG000'}, {'value': '0.475', 'spread': '0.380', 'groupId': 'OG001'}, {'value': '1.46', 'spread': '0.596', 'groupId': 'OG002'}, {'value': '2.15', 'spread': '1.47', 'groupId': 'OG003'}, {'value': '1.94', 'spread': '1.53', 'groupId': 'OG004'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'baseline to week 24, then week 28', 'description': 'Pharmacokinetic Concentrations\n\nThis outcome only applies to patients who received at least one dose of VAY739 (so not applicable to placebo)', 'unitOfMeasure': 'ug/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Safety set (SAF): included all patients who received at least one dose of study medication. Patients were analyzed according to treatment received and the actual stratum at baseline. The safety set was used in the analysis of all safety variables.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'FG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'FG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'FG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'FG004', 'title': 'VAY736 - 150 mg', 'description': 'Placebo patients in Period 2 switched to VAY736 - 150 mg s.c. administration every 4 weeks in Period 3 (Period 3 = 28 weeks)'}, {'id': 'FG005', 'title': 'VAY736 300 mg - Placebo', 'description': 'VAY736 300 mg patients in Period 2 re-randomized to Placebo every 4 weeks in Period 3 (Period 3 = 28 weeks)'}, {'id': 'FG006', 'title': 'VAY736 300 mg - VAY736 300 mg', 'description': 'VAY736 300 mg patients in Period 2 re-randomized to VAY736 300 mg every 4 weeks in Period 3 (Period 3 = 28 weeks)'}], 'periods': [{'title': 'Period 2 (Randomized Set: Up to Week 24)', 'milestones': [{'type': 'STARTED', 'comment': 'All randomized patients were included in the Full Analysis Set (FAS) and Safety Set (SAF)', 'achievements': [{'groupId': 'FG000', 'numSubjects': '49'}, {'groupId': 'FG001', 'numSubjects': '47'}, {'groupId': 'FG002', 'numSubjects': '47'}, {'groupId': 'FG003', 'numSubjects': '47'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '47'}, {'groupId': 'FG001', 'numSubjects': '42'}, {'groupId': 'FG002', 'numSubjects': '43'}, {'groupId': 'FG003', 'numSubjects': '46'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '5'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'Withdrawal of Informed Consent', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'New therapy for indication', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'Non-compliance with treatment', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'Pregnancy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}]}, {'title': 'Period 3 (Randomized Set / Weeks: 24-52)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '47'}, {'groupId': 'FG005', 'numSubjects': '22'}, {'groupId': 'FG006', 'numSubjects': '21'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '42'}, {'groupId': 'FG005', 'numSubjects': '22'}, {'groupId': 'FG006', 'numSubjects': '17'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '5'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '4'}]}], 'dropWithdraws': [{'type': 'Patient/guardian decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '5'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '2'}]}, {'type': 'Pregnancy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '1'}]}]}, {'title': 'Period 4 (Safety Follow-Up)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '47'}, {'groupId': 'FG002', 'numSubjects': '47'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '46'}, {'groupId': 'FG005', 'numSubjects': '22'}, {'groupId': 'FG006', 'numSubjects': '20'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '41'}, {'groupId': 'FG002', 'numSubjects': '43'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '42'}, {'groupId': 'FG005', 'numSubjects': '20'}, {'groupId': 'FG006', 'numSubjects': '20'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '4'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'New therapy for indication', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'Withdrawal of informed consent', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '2'}, {'groupId': 'FG006', 'numSubjects': '0'}]}]}], 'recruitmentDetails': '190 Patients were enrolled from 56 centers in 19 countries.', 'preAssignmentDetails': 'Patients who were in the placebo arm in Period 2 were switched to VAY736 - 150mg s.c. administration every 4 weeks in Period 3.\n\nAt the end of Period 2, patients from the VAY736 300mg every 4 weeks arm were re-randomized to either i) double-blind VAY736 300mg every 4 weeks or ii) double-blind placebo every four weeks. All other patients proceeded directly from Period 2 to Period 4 (Safety Follow-Up).'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'BG000'}, {'value': '47', 'groupId': 'BG001'}, {'value': '47', 'groupId': 'BG002'}, {'value': '47', 'groupId': 'BG003'}, {'value': '190', 'groupId': 'BG004'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'BG001', 'title': 'VAY736 - 5 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'BG002', 'title': 'VAY736 - 50 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'BG003', 'title': 'VAY736 - 300 mg (Up to Week 24)', 'description': 'Period 2 (Double blind Placebo s.c. administration every 4 weeks (q4w) for a 24-week period)'}, {'id': 'BG004', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '47.9', 'spread': '12.44', 'groupId': 'BG000'}, {'value': '52.5', 'spread': '13.64', 'groupId': 'BG001'}, {'value': '51.0', 'spread': '11.12', 'groupId': 'BG002'}, {'value': '49.1', 'spread': '15.41', 'groupId': 'BG003'}, {'value': '50.9', 'spread': '13.48', 'groupId': 'BG004'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '47', 'groupId': 'BG000'}, {'value': '46', 'groupId': 'BG001'}, {'value': '41', 'groupId': 'BG002'}, {'value': '46', 'groupId': 'BG003'}, {'value': '180', 'groupId': 'BG004'}]}, {'title': 'Male', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '10', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'Asian', 'categories': [{'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '22', 'groupId': 'BG004'}]}]}, {'title': 'Black or African American', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}]}]}, {'title': 'White', 'categories': [{'measurements': [{'value': '44', 'groupId': 'BG000'}, {'value': '42', 'groupId': 'BG001'}, {'value': '37', 'groupId': 'BG002'}, {'value': '42', 'groupId': 'BG003'}, {'value': '165', 'groupId': 'BG004'}]}]}, {'title': 'Unknown', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-01-16', 'size': 4982389, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2022-07-13T17:30', 'hasProtocol': True}, {'date': '2019-07-27', 'size': 1674299, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2022-07-13T17:33', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': "This was a randomized, double-blind, placebo-controlled, multicenter, parallel-group trial which planned to enroll approximately 180 patients with moderate to severe primary Sjögren's syndrome. The study was divided into 4 study periods:\n\nPeriod 1: 4-week Screening to assess patient eligibility.\n\nPeriod 2: 24-week Blinded treatment period.\n\nPeriod 3: An extended blinded treatment period of 28 weeks. After Week 24 assessments, patients in the ianalumab 300 mg arm were re-randomized in a 1:1 ratio to either continue on ianalumab 300 mg s.c. q4w or switch to matching placebo up to Week 52.\n\nPeriod 4: Post-treatment safety follow-up period. Patients who prematurely discontinued the study treatment at any time point or completed the treatment as planned entered the safety follow-up period."}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 190}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-06-27', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-01', 'dispFirstSubmitDate': '2020-07-16', 'completionDateStruct': {'date': '2021-09-23', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-01-06', 'studyFirstSubmitDate': '2016-11-03', 'resultsFirstSubmitDate': '2022-07-13', 'studyFirstSubmitQcDate': '2016-11-09', 'dispFirstPostDateStruct': {'date': '2024-10-29', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2025-01-07', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-10-28', 'studyFirstPostDateStruct': {'date': '2016-11-15', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2024-10-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-06-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Least Squares Mean Change From Baseline in ESSDAI Score at Week 24', 'timeFrame': 'Baseline, Week 24', 'description': "The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status."}], 'secondaryOutcomes': [{'measure': 'Least Squares Mean Change From Baseline in ESSDAI Score at Weeks 4, 8, 12, and 16', 'timeFrame': 'Baseline, Week 4, Week 8, Week 12, Week 16', 'description': "The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score ranging 0-123. Higher scores on the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states. A negative change from baseline indicates improvement in disease status."}, {'measure': 'Least Squares Mean Change From Baseline in ESSPRI Score at Week 24', 'timeFrame': 'Baseline, Week 24', 'description': "The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome."}, {'measure': 'Least Squares Mean Change From Baseline in ESSPRI Score at Weeks 4, 8, 12 and 16', 'timeFrame': 'Baseline, Week 4, Week 8, Week 12, Week 16', 'description': "The EULAR Sjörgen's Syndrome Patient Reported Index (ESSPRI) is an established disease outcome measure for Sjögren's syndrome that is calculated by averaging the scales for pain, fatigue and dryness. The total score is the mean score of the 3 scales and ranges between 0 and 10 with higher values indicating more severity of symptoms. A negative change from baseline is a favorable outcome."}, {'measure': 'Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score Over 24 Weeks', 'timeFrame': 'Baseline, Week 24', 'description': "The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue."}, {'measure': 'Least Squares Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Score at Weeks 4, 8, 12 and 16', 'timeFrame': 'Baseline, Weeks 4, 8, 12 and 16', 'description': "The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F v4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the previous week. The level of fatigue is measured on a four-point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The global score ranges between 0 and 52, with higher scores indicating less fatigue."}, {'measure': 'Least Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) Over 24 Weeks', 'timeFrame': 'Baseline, Week 24', 'description': 'The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).'}, {'measure': 'Least Squares Mean Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component (PCS) and Mental Component (MCS) at Weeks 4, 8, 12 and 16', 'timeFrame': 'Baseline, Weeks 4, 8, 12 and 16', 'description': 'The SF36 includes 8 scale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) and two summary scores, the physical and mental component scores. The first four and last four scales comprise physical and mental component scores, respectively. The range of scores of the physical component (PCS) and mental component (MCS) is 0 (lowest or worst possible level of functioning) to 100 (highest or best possible level of functioning).'}, {'measure': "Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) Over 24 Weeks", 'timeFrame': 'Baseline, 24 weeks', 'description': 'Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.'}, {'measure': "Least Squares Mean Change From Baseline in Physician's Global Assessment (PhGA) of Patient's Overall Disease Activity Using Patient Visual Analog Scale (VAS) at Weeks 4, 8, 12 and 16", 'timeFrame': 'Baseline, Weeks 4, 8, 12 and 16', 'description': 'Physician global assessment of overall disease activity (PhGA) was performed using a 100 mm visual analogue scale (VAS) ranging from no disease activity (score 0) to maximal disease activity (score 100), after the question "Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today". A negative change from baseline is a favourable outcome.'}, {'measure': "Patient's Global Assessment (PaGA) Score at Weeks 4, 8, 12, 16 and 24", 'timeFrame': 'Weeks 4, 8, 12, 16 and 24', 'description': 'The PaGA of disease activity was performed using a 100 mm Visual Analog Scale (VAS) ranging from 0 (no disease activity) to 100 (maximal disease activity), in response to the question "Considering all the ways Sjögren\'s syndrome affects you, please draw a line on the scale to indicate how well you are doing today". A negative change from baseline is a favourable outcome.'}, {'measure': 'Least Squares Mean Change From Baseline in Salivary Flow Rate at Week 24', 'timeFrame': 'Baseline, 24 weeks', 'description': 'Change from baseline in salivary flow rate (unstimulated and stimulated) at 24 weeks as compared to placebo.\n\nUnstimulated saliva is a mix of serous and mucous secretions coming primarily from the submandibular and minor salivary glands. The parotid gland produces the largest volume of stimulated saliva. Stimulated saliva accounts for 80-90% of daily salivary production.'}, {'measure': 'Percent Change From Baseline in Whole Blood CD19+ B-cell Counts.', 'timeFrame': 'Baseline, Week 24, Week 28', 'description': 'B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \\>= 50 cells/μL) were analyzed by descriptive statistics.\n\nBaseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.'}, {'measure': 'Kaplan-Meier Analysis for Time to Recovery to Baseline Like Values for B-cell Counts', 'timeFrame': 'Up to two years from last dose patient received.', 'description': 'B-cell counts were measured before, during and after treatment with VAY736. After stopping VAY736 treatment they were used to monitor patients for time to recovery of adequate CD19+ B cell counts prior to discharge from the study. Change from baseline in B-cell counts before, during and after treatment with VAY736 as well as the time to recover to baseline like values (defined as at least 80% of baseline counts or \\>= 50 cells/μL) were analyzed by descriptive statistics.\n\nBaseline was defined as the last assessment performed on or prior to the date of administration of the first dose of study treatment.'}, {'measure': 'Peak Serum Concentration of VAY736', 'timeFrame': 'baseline to week 24, then week 28', 'description': 'Pharmacokinetic Concentrations\n\nThis outcome only applies to patients who received at least one dose of VAY739 (so not applicable to placebo)'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Sjogren', 'VAY736', 'ianalumab', 'pSS'], 'conditions': ['Primary Sjogren Syndrome']}, 'referencesModule': {'references': [{'pmid': '34861168', 'type': 'DERIVED', 'citation': "Bowman SJ, Fox R, Dorner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022 Jan 8;399(10320):161-171. doi: 10.1016/S0140-6736(21)02251-0. Epub 2021 Nov 30."}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study was to determine the dose-response relationship of VAY736 for key efficacy and safety parameters', 'detailedDescription': 'This was a randomized, double-blind, placebo-controlled, multicenter, parallel-group trial that was divided into 4 study periods.\n\nPeriod 1: A screening period of 4 weeks to assess patient eligibility. Patients could be re-screened only once, and no study-related re-screening procedure could be performed prior to written re-consent by the patient.\n\nPeriod 2: A blinded treatment period of 24 weeks. At baseline, eligible patients were randomized to one of three ianalumab dose arms (VAY736 5 mg, 50 mg or 300 mg s.c.) or a placebo arm (placebo s.c.). Blinded study drug was administered every four weeks (q4w) for a 24-week period.\n\nExcept for Japan, randomization was stratified by baseline ESSDAI score (\\<10 or ≥10 based on weighted scores). Separate blocks of randomization numbers were generated for patients in Japan versus the other countries participating to ensure that Japanese patients were equally distributed across all treatment groups in the study.\n\nThe primary endpoint was assessed at the end of Period 2 (Week 24). Treatment assignment in Period 2 remained double-blinded until the end of Period 3.\n\nPeriod 3: An extended blinded treatment period of 28 weeks. After Week 24 assessments, patients in the ianalumab 300 mg arm were re-randomized in a 1:1 ratio to either continue on ianalumab 300 mg s.c. q4w or switch to matching placebo up to Week 52. Patients who received placebo during Period 2 were switched to ianalumab 150 mg s.c q4w up to Week 52. Patients who received 5 mg and 50 mg s.c. in Period 2 proceeded directly to safety follow-up (Period 4). Treatment assignment in Period 3 remained double-blinded.\n\nPeriod 4: A post-treatment safety follow-up period. Patients who prematurely discontinued the study treatment at any time point or completed the treatment as planned entered the safety follow-up period. The minimum required duration of follow-up in the study was 20 weeks from the last administration of the study treatment (mandatory follow-up). The maximum duration of the follow-up was 2 years from the last dose of the study treatment, and it was defined by the level of recovery of CD19+ B-cells: conditional follow up (with reduced visit frequency) until CD19+ B-cell levels return to at least 80% of baseline or 50 cells/µL, whichever occurred first. Patients who had not yet recovered their B-cell counts two years after last ianalumab dosing were discharged from the study and had undergone their End of Study (EoS) visit. Patients who were treated with another immunomodulatory or immunosuppressive treatment (e.g., azathioprine, cyclophosphamide, high dose glucocorticosteroids) after completion of the minimum 20-week safety follow-up period were excluded from further safety follow-up.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Fulfilled revised American European Consensus Group criteria for pSS\n* Seropositive at screening for anti-Ro/SSA antibodies\n* Screening ESSDAI value \\>=6 scored from 7 domains: articular, cutaneous, glandular, lymphoadenopathy, constitutional, biologic and hematologic.\n\nExclusion Criteria:\n\n* Secondary Sjogren's syndrome\n* Use of other investigational drugs\n* Active viral, bacterial or other infections\n* Positive hepatitis B, hepatitis C, HIV or tuberculosis test results at screening"}, 'identificationModule': {'nctId': 'NCT02962895', 'briefTitle': "Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)", 'organization': {'class': 'INDUSTRY', 'fullName': 'Novartis'}, 'officialTitle': "Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS)", 'orgStudyIdInfo': {'id': 'CVAY736A2201'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'VAY736 dose 1 - 5mg', 'description': 'VAY736 low', 'interventionNames': ['Biological: VAY736']}, {'type': 'EXPERIMENTAL', 'label': 'VAY736 dose 2 - 50mg', 'description': 'VAY736 medium', 'interventionNames': ['Biological: VAY736']}, {'type': 'EXPERIMENTAL', 'label': 'VAY736 dose 3 - 300 mg', 'description': 'VAY736 high', 'interventionNames': ['Biological: VAY736']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Placebo control', 'interventionNames': ['Other: Placebo']}], 'interventions': [{'name': 'VAY736', 'type': 'BIOLOGICAL', 'otherNames': ['Ianalumab'], 'description': 'VAY736', 'armGroupLabels': ['VAY736 dose 1 - 5mg', 'VAY736 dose 2 - 50mg', 'VAY736 dose 3 - 300 mg']}, {'name': 'Placebo', 'type': 'OTHER', 'description': 'Placebo control', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '33324', 'city': 'Plantation', 'state': 'Florida', 'country': 'United States', 'facility': 'Integral Rheumatology and Immunology Specialists IRIS', 'geoPoint': {'lat': 26.13421, 'lon': -80.23184}}, {'zip': '46202', 'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'facility': 'Indiana Univ School of Dentistry', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '21224', 'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'facility': 'The John Hopkins Jerome L Greene Sjogren', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '02111', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Tufts School of Dental Medicine', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '14618', 'city': 'Rochester', 'state': 'New York', 'country': 'United States', 'facility': 'AAIR Research Center', 'geoPoint': {'lat': 43.15478, 'lon': -77.61556}}, {'zip': '15213', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'UPMC', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '15090', 'city': 'Wexford', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Advanced Rheumatology and Arthritis Wellness Center', 'geoPoint': {'lat': 40.62646, 'lon': -80.05589}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Baylor College Of Medicine', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'First Outpatient Research Unit', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': 'C1055AAF', 'city': 'Ciudad Autonoma de Bs As', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Novartis Investigative Site'}, {'zip': '1117', 'city': 'CABA', 'country': 'Argentina', 'facility': 'Novartis Investigative Site'}, {'zip': '5000', 'city': 'Córdoba', 'country': 'Argentina', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -31.40648, 'lon': -64.18853}}, {'zip': 'X5016KEH', 'city': 'Córdoba', 'country': 'Argentina', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -31.40648, 'lon': -64.18853}}, {'zip': '8036', 'city': 'Graz', 'country': 'Austria', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.06733, 'lon': 15.44197}}, {'zip': '1070', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '3000', 'city': 'Leuven', 'country': 'Belgium', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'zip': '7500710', 'city': 'Santiago', 'country': 'Chile', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '8207257', 'city': 'Santiago', 'country': 'Chile', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '29200', 'city': 'Brest', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 48.39029, 'lon': -4.48628}}, {'zip': '59037', 'city': 'Lille', 'country': 'France', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'zip': '13353', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '79106', 'city': 'Freiburg im Breisgau', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.9959, 'lon': 7.85222}}, {'zip': '81377', 'city': 'München', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.60698, 'lon': 13.31243}}, {'zip': '97080', 'city': 'Würzburg', 'country': 'Germany', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 49.79391, 'lon': 9.95121}}, {'zip': 'H-1097', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '6720', 'city': 'Szeged', 'country': 'Hungary', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.253, 'lon': 20.14824}}, {'zip': '52621', 'city': 'Ramat Gan', 'country': 'Israel', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}}, {'zip': '20089', 'city': 'Rozzano', 'state': 'MI', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'zip': '00161', 'city': 'Roma', 'state': 'RM', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 44.99364, 'lon': 11.10642}}, {'zip': '33100', 'city': 'Udine', 'state': 'UD', 'country': 'Italy', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.0693, 'lon': 13.23715}}, {'zip': '457 8510', 'city': 'Nagoya', 'state': 'Aichi-ken', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'zip': '857-1165', 'city': 'Sasebo', 'state': 'Nagasaki', 'country': 'Japan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 33.16834, 'lon': 129.72502}}, {'zip': '173-8610', 'city': 'Itabashi-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Novartis Investigative Site'}, {'zip': '160 8582', 'city': 'Shinjuku-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Novartis Investigative Site'}, {'zip': '3015 GD', 'city': 'Rotterdam', 'state': 'South Holland', 'country': 'Netherlands', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}, {'zip': '20-954', 'city': 'Lublin', 'country': 'Poland', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '2801 951', 'city': 'Almada', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.67902, 'lon': -9.1569}}, {'zip': '1050-034', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '1649 035', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '4099-001', 'city': 'Porto', 'country': 'Portugal', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.1485, 'lon': -8.61097}}, {'zip': '500283', 'city': 'Brasov', 'country': 'Romania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 45.64861, 'lon': 25.60613}}, {'zip': '400006', 'city': 'Cluj-Napoca', 'country': 'Romania', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'zip': '115522', 'city': 'Moscow', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'zip': '460000', 'city': 'Orenburg', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 51.76712, 'lon': 55.09883}}, {'zip': '195257', 'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'zip': '620028', 'city': 'Yekaterinburg', 'country': 'Russia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 56.85733, 'lon': 60.61529}}, {'zip': '36200', 'city': 'Vigo', 'state': 'Pontevedra', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 42.23282, 'lon': -8.72264}}, {'zip': '38320', 'city': 'San Cristóbal de La Laguna', 'state': 'Santa Cruz De Tenerife', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 28.4853, 'lon': -16.32014}}, {'zip': '08041', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '81346', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '40447', 'city': 'Taichung', 'country': 'Taiwan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '407219', 'city': 'Taichung', 'country': 'Taiwan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '11490', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': 'B15 2TH', 'city': 'Birmingham', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'zip': 'L9 7AL', 'city': 'Liverpool', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'zip': 'SSO 0RY', 'city': 'Southend', 'country': 'United Kingdom', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 55.31667, 'lon': -5.63333}}], 'overallOfficials': [{'name': 'Novartis Pharmaceuticals', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Novartis Pharmaceuticals'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novartis Pharmaceuticals', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}